Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8337824 | VIFOR PHARMA | Linear polyol stabilized polyfluoroacrylate compositions |
May, 2030
(6 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8475780 | VIFOR PHARMA | Ion binding polymers and uses thereof |
Mar, 2024
(6 months from now) | |
US8778324 | VIFOR PHARMA | Ion binding polymers and uses thereof |
Mar, 2024
(6 months from now) | |
US8287847 | VIFOR PHARMA | Ion binding polymers and uses thereof |
Mar, 2024
(6 months from now) | |
US8889115 | VIFOR PHARMA | Ion binding polymers and uses thereof |
Mar, 2024
(6 months from now) | |
US10485821 | VIFOR PHARMA | Ion binding polymers and uses thereof |
Mar, 2024
(6 months from now) | |
US7556799 | VIFOR PHARMA | Ion binding polymers and uses thereof |
Feb, 2025
(1 year, 5 months from now) | |
US8216560 | VIFOR PHARMA | Ion binding polymers and uses thereof |
Mar, 2027
(3 years from now) | |
US8282913 | VIFOR PHARMA | Ion binding polymers and uses thereof |
May, 2027
(3 years from now) | |
US8147873 | VIFOR PHARMA | Methods and compositions for treatment of ion imbalances |
Jun, 2028
(4 years from now) | |
US9925212 | VIFOR PHARMA | Potassium-binding agents for treating hypertension and hyperkalemia |
Oct, 2033
(10 years from now) | |
US9492476 | VIFOR PHARMA | Potassium-binding agents for treating hypertension and hyperkalemia |
Oct, 2033
(10 years from now) | |
US11123363 | VIFOR PHARMA | Potassium-binding agents for treating hypertension and hyperkalemia |
Oct, 2033
(10 years from now) |
Drugs and Companies using PATIROMER SORBITEX CALCIUM ingredient
Market Authorisation Date: 21 October, 2015
Treatment: Treatment of hyperkalemia
Dosage: POWDER;ORAL
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic